Maternal use of recreational drugs and neuroblastoma in offspring: a report from the Children's Oncology Group (United States)

被引:32
|
作者
Bluhm, EC
Daniels, J
Pollock, BH
Olshan, AF
机构
[1] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[2] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA
[3] NCI, Canc Prevent Fellowship Program, Div Canc Prevent, NIH, Bethesda, MD 20892 USA
[4] Univ Texas, Hlth Sci Ctr, Ctr Biostat & Epidemiol, San Antonio, TX USA
关键词
neuroblastoma; marijuana smoking; case-control studies; prenatal exposure delayed effects; maternal exposure;
D O I
10.1007/s10552-005-0580-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To evaluate whether maternal use of recreational drugs around conception and pregnancy influences the risk of childhood neuroblastoma. Methods Self-reported use of recreational drugs from one month prior to pregnancy until diagnosis was assessed among mothers of 538 children with neuroblastoma (diagnosed 1992-1994 and identified through the Children's Cancer Group and Pediatric Oncology Group) and 504 age-matched controls (identified by random-digit dialing). Odds ratios (OR) and 95% confidence intervals (CI) were estimated using unconditional logistic regression, adjusting for age at diagnosis and household income. Results Maternal use of any illicit or recreational drug around pregnancy was associated with an increased risk of neuroblastoma in offspring (OR = 1.82, 95% CI: 1.13, 3.00), particularly use of marijuana in the first trimester of pregnancy (OR = 4.75, 95% CI: 1.55, 16.48). Marijuana use in the month before pregnancy did not increase risk. The effect of gestational marijuana exposure was strongest in subjects diagnosed before age one. Evaluation of recreational drugs other than marijuana was limited by infrequent use, and analyses of drug use by fathers were not carried out due to missing data. Conclusions Maternal recreational drug use and marijuana use during pregnancy were associated with increased risk of neuroblastoma in offspring. Further examination of these drugs and the risk of childhood cancer is warranted.
引用
收藏
页码:663 / 669
页数:7
相关论文
共 50 条
  • [41] Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641
    Strother, Douglas R.
    London, Wendy B.
    Schmidt, Mary Lou
    Brodeur, Garrett M.
    Shimada, Hiroyuki
    Thorner, Paul
    Collins, Margaret H.
    Tagge, Edward
    Adkins, Stanton
    Reynolds, C. Patrick
    Murray, Kevin
    Lavey, Robert S.
    Matthay, Katherine K.
    Castleberry, Robert
    Maris, John M.
    Cohn, Susan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) : 1842 - 1848
  • [42] Comparability and Representativeness of Control Groups in a Case-Control Study of Infant Leukemia: A Report From the Children's Oncology Group
    Puumala, Susan E.
    Spector, Logan G.
    Robison, Leslie L.
    Bunin, Greta R.
    Olshan, Andrew F.
    Linabery, Amy M.
    Roesler, Michelle A.
    Blair, Cindy K.
    Ross, Julie A.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 170 (03) : 379 - 387
  • [43] Examination of Veteran Fathers' Parenting and Their Adolescent Children's Substance Use in the United States
    Lipari, Rachel
    Palen, Lori-Ann
    Ashley, Olivia Silber
    Penne, Michael
    Kan, Marni
    Pemberton, Michael
    SUBSTANCE USE & MISUSE, 2017, 52 (06) : 698 - 708
  • [44] Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group
    Streby, Keri A.
    Parisi, Marguerite T.
    Shulkin, Barry L.
    LaBarre, Brian
    Bagatell, Rochelle
    Diller, Lisa
    Grupp, Stephan A.
    Matthay, Katherine K.
    Voss, Stephan D.
    Yu, Alice L.
    London, Wendy B.
    Park, Julie R.
    Yanik, Gregory A.
    Naranjo, Arlene
    PEDIATRIC BLOOD & CANCER, 2023, 70 (08)
  • [45] Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies - A report from the Children's Cancer Group study
    Rudnick, E
    Khakoo, Y
    Antunes, NL
    Seeger, RC
    Brodeur, GM
    Shimada, H
    Gerbing, RB
    Stram, DO
    Matthay, KK
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (06): : 612 - 622
  • [46] Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group
    Knight, Kristin R.
    Chen, Lu
    Freyer, David
    Aplenc, Richard
    Bancroft, Mary
    Bliss, Bonnie
    Dang, Ha
    Gillmeister, Biljana
    Hendershot, Eleanor
    Kraemer, Dale F.
    Lindenfeld, Lanie
    Meza, Jane
    Neuwelt, Edward A.
    Pollock, Brad H.
    Sung, Lillian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) : 440 - +
  • [47] Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group
    Laetsch, Theodore W.
    Roy, Angshumoy
    Xu, Lin
    Black, Jennifer O.
    Coffin, Cheryl M.
    Chi, Yueh-Yun
    Tian, Jing
    Spunt, Sheri L.
    Hawkins, Douglas S.
    Bridge, Julia A.
    Parsons, D. Williams
    Skapek, Stephen X.
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3888 - 3897
  • [48] Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study
    L L Wang
    R Teshiba
    N Ikegaki
    X X Tang
    A Naranjo
    W B London
    M D Hogarty
    J M Gastier-Foster
    A T Look
    J R Park
    J M Maris
    S L Cohn
    R C Seeger
    S Asgharzadeh
    H Shimada
    British Journal of Cancer, 2015, 113 : 57 - 63
  • [49] Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification
    Feng, Lijuan
    Kan, Ying
    Wang, Wei
    Wang, Chao
    Zhang, Hui
    Xie, Peng
    Yang, Jigang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (18) : 16377 - 16390
  • [50] Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
    Wang, L. L.
    Teshiba, R.
    Ikegaki, N.
    Tang, X. X.
    Naranjo, A.
    London, W. B.
    Hogarty, M. D.
    Gastier-Foster, J. M.
    Look, A. T.
    Park, J. R.
    Maris, J. M.
    Cohn, S. L.
    Seeger, R. C.
    Asgharzadeh, S.
    Shimada, H.
    BRITISH JOURNAL OF CANCER, 2015, 113 (01) : 57 - 63